Meeting
2019 ASCO Annual Meeting
c-AMP/MAPK dysregulation and its impact on survival and response to immunotherapy in advanced melanomas.
Authors
Rami Al-Rohil
Duke University Medical Center, Durham, NC
Etan Marks , Varshini Vasudevaraja , Stephen Kelly , Matija Snuderl , Douglas Buckner Johnson , George Jour , Rami Al-Rohil
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3086)
DOI
10.1200/JCO.2019.37.15_suppl.3086
Abstract #
3086
Poster Bd #
78
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
First Author: Yuval Shaked
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Differences in immune profiles of metastatic melanoma patients treated with anti-CTLA-4 and anti-PD-1 combined immunotherapy.
First Author: Tuba Nur Gide
Poster
2015 ASCO Annual Meeting
Deep profiling of tumor immune microenvironment (TME) with fluorescence activated cell sorting (FACS) in advanced melanoma.
First Author: Kimberly Loo
Poster
2013 ASCO Annual Meeting
An open-label, randomized, phase II study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) given sequentially with ipilimumab in patients (pts) with advanced or metastatic melanoma (MEL).
First Author: F. Stephen Hodi